Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain.

[1]  Yingkai Zhang,et al.  Poly(ethylene glycol)-block-poly(d,l-lactide acid) micelles anchored with angiopep-2 for brain-targeting delivery , 2011, Journal of drug targeting.

[2]  W. Hennink,et al.  In Vivo Methods to Study Uptake of Nanoparticles into the Brain , 2010, Pharmaceutical Research.

[3]  Rongqin Huang,et al.  Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[4]  M A Vandelli,et al.  Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[5]  Wenwei Tang,et al.  Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[6]  W. Banks,et al.  Transport across the Blood-Brain Barrier of Pluronic Leptin , 2010, Journal of Pharmacology and Experimental Therapeutics.

[7]  J. Kreuter,et al.  Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[8]  Shiladitya Sengupta,et al.  Shape effect of carbon nanovectors on angiogenesis. , 2010, ACS nano.

[9]  Chen Jiang,et al.  Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. , 2009, Biomaterials.

[10]  Wei Feng,et al.  Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier. , 2009, International journal of pharmaceutics.

[11]  U. Massing,et al.  Uptake of apolipoprotein E fragment coupled liposomes by cultured brain microvessel endothelial cells and intact brain capillaries , 2009, Journal of drug targeting.

[12]  D. Begley,et al.  Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[13]  Guojun Bu,et al.  Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy , 2009, Nature Reviews Neuroscience.

[14]  J. Kreuter,et al.  Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[15]  William A Banks,et al.  Developing drugs that can cross the blood-brain barrier: applications to Alzheimer's disease , 2008, BMC Neuroscience.

[16]  G. Golomb,et al.  Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[17]  S. Krähenbühl,et al.  The human brain endothelial cell line hCMEC/D3 as a human blood‐brain barrier model for drug transport studies , 2008, Journal of neurochemistry.

[18]  V. Labhasetwar,et al.  TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. , 2008, Biomaterials.

[19]  R. Davey,et al.  Mouse mammary tumor virus uses mouse but not human transferrin receptor 1 to reach a low pH compartment and infect cells , 2008, Virology.

[20]  G. Schenk,et al.  Drug targeting to the brain , 2008, Annual review of pharmacology and toxicology.

[21]  R. Béliveau,et al.  Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep‐2 , 2008, British journal of pharmacology.

[22]  Ke-Xin Zhang,et al.  Shape effects of nanoparticles conjugated with cell-penetrating peptides (HIV Tat PTD) on CHO cell uptake. , 2008, Bioconjugate chemistry.

[23]  Michel Demeule,et al.  Identification and Design of Peptides as a New Drug Delivery System for the Brain , 2008, Journal of Pharmacology and Experimental Therapeutics.

[24]  E. Morgan,et al.  Iron trafficking inside the brain , 2007, Journal of neurochemistry.

[25]  E. Shusta,et al.  Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation , 2007, Pharmaceutical Research.

[26]  M. Vitek,et al.  COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury. , 2007, Journal of neurotrauma.

[27]  P. Gaillard,et al.  A novel opportunity for targeted drug delivery to the brain. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[28]  C. Colton,et al.  Apolipoprotein E-Derived Peptides Ameliorate Clinical Disability and Inflammatory Infiltrates into the Spinal Cord in a Murine Model of Multiple Sclerosis , 2006, Journal of Pharmacology and Experimental Therapeutics.

[29]  M. Michaelis,et al.  Covalent Linkage of Apolipoprotein E to Albumin Nanoparticles Strongly Enhances Drug Transport into the Brain , 2006, Journal of Pharmacology and Experimental Therapeutics.

[30]  M. Wauben,et al.  Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. , 2006, Arthritis and rheumatism.

[31]  A. Rawat,et al.  Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles , 2006, Journal of drug targeting.

[32]  J. Greenwood,et al.  Blood‐brain barrier‐specific properties of a human adult brain endothelial cell line , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  W. Banks,et al.  Antagonists of growth hormone-releasing hormone cross the blood-brain barrier : A potential applicability to treatment of brain tumors , 2005 .

[34]  T. Nagai,et al.  Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: in vitro and in vivo studies. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[35]  S. Krähenbühl,et al.  Targeting of daunomycin using biotinylated immunoliposomes: Pharmacokinetics, tissue distribution and in vitro pharmacological effects , 2005, Journal of drug targeting.

[36]  Meindert Danhof,et al.  Targeting liposomes with protein drugs to the blood-brain barrier in vitro. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[37]  A. Boer,et al.  Diphtheria toxin receptor-targeted brain drug delivery , 2005 .

[38]  H. Kusuhara,et al.  Investigation of Efflux Transport of Dehydroepiandrosterone Sulfate and Mitoxantrone at the Mouse Blood-Brain Barrier: A Minor Role of Breast Cancer Resistance Protein , 2005, Journal of Pharmacology and Experimental Therapeutics.

[39]  Yiguang Jin,et al.  The Effect of RMP-7 and its Derivative on Transporting Evens Blue Liposomes into the Brain , 2004, Drug delivery.

[40]  P. Gaillard,et al.  The role of drug transporters at the blood-brain barrier. , 2003, Annual review of pharmacology and toxicology.

[41]  Peter Ramge,et al.  Apolipoprotein-mediated Transport of Nanoparticle-bound Drugs Across the Blood-Brain Barrier , 2002, Journal of drug targeting.

[42]  W. Pardridge,et al.  Brain-specific expression of an exogenous gene after i.v. administration , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[43]  I. Fichtner,et al.  Influence of Surface-Modifying Surfactants on the Pharmacokinetic Behavior of 14C-Poly (Methylmethacrylate) Nanoparticles in Experimental Tumor Models , 2001, Pharmaceutical Research.

[44]  U. Nielsen,et al.  Tumor targeting using anti-her2 immunoliposomes. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[45]  S. Pizzo,et al.  Downregulation of Microglial Activation by Apolipoprotein E and ApoE-Mimetic Peptides , 2001, Experimental Neurology.

[46]  Y. Sawada,et al.  Characteristics of Choline Transport Across the Blood-Brain Barrier in Mice: Correlation with In Vitro Data , 2000, Pharmaceutical Research.

[47]  Y. Sawada,et al.  Comparison of blood-brain barrier permeability in mice and rats using in situ brain perfusion technique. , 2000, American journal of physiology. Heart and circulatory physiology.

[48]  A. Kastin,et al.  Mahogany (1377-1428) enters brain by a saturable transport system. , 2000, The Journal of pharmacology and experimental therapeutics.

[49]  B. Engelhardt,et al.  Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. , 2000, The Journal of pharmacology and experimental therapeutics.

[50]  M. Freeman,et al.  A nontoxic diphtheria toxin analogue inhibits neonatal bladder smooth muscle cell proliferation. , 2000, The Journal of urology.

[51]  J. Drewe,et al.  Endocytosis and Transcytosis of an Immunoliposome-Based Brain Drug Delivery System , 2000, Journal of drug targeting.

[52]  C. Lok,et al.  The transferrin receptor: role in health and disease. , 1999, The international journal of biochemistry & cell biology.

[53]  S. Higashiyama,et al.  Heparin-binding epidermal growth factor-like growth factor mRNA expression in neonatal rat brain with hypoxic/ischemic injury , 1999, Brain Research.

[54]  B. Engelhardt,et al.  Immunohistochemical localization of the murine transferrin receptor (TfR) on blood–tissue barriers using a novel anti-TfR monoclonal antibody , 1998, Histochemistry and Cell Biology.

[55]  M. Klagsbrun,et al.  Heparin-binding EGF-like growth factor. , 1997, Biochimica et biophysica acta.

[56]  R. Schiffelers,et al.  Human recombinant apolipoprotein E-enriched liposomes can mimic low-density lipoproteins as carriers for the site-specific delivery of antitumor agents. , 1997, Molecular pharmacology.

[57]  John W. Park,et al.  Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. , 1997, Biochemistry.

[58]  J. Huwyler,et al.  Brain drug delivery of small molecules using immunoliposomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[59]  B. Hyman,et al.  LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted β-amyloid precursor protein and mediates its degradation , 1995, Cell.

[60]  W. Banks,et al.  Murine tumor necrosis factor alpha is transported from blood to brain in the mouse , 1993, Journal of Neuroimmunology.

[61]  W. Pardridge,et al.  Capillary Depletion Method for Quantification of Blood–Brain Barrier Transport of Circulating Peptides and Plasma Proteins , 1990, Journal of neurochemistry.

[62]  R. Rappuoli,et al.  The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. , 1984, Nucleic acids research.

[63]  L. Huang,et al.  Use of radiolabeled hexadecyl cholesteryl ether as a liposome marker , 1982, Lipids.

[64]  W. Pardridge.  The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.

[65]  Robin Hull,et al.  A good practice guide to the administration of substances and removal of blood, including routes and volumes , 2001, Journal of applied toxicology : JAT.

[66]  R. New,et al.  Liposomes : a practical approach , 1990 .

[67]  R. Schulte,et al.  Expression of transferrin receptor on murine hematopoietic progenitors. , 1984, Cellular immunology.